Wolfgang Löscher Selected Research

Status Epilepticus (Complex Partial Status Epilepticus)

10/2021	Scopolamine prevents aberrant mossy fiber sprouting and facilitates remission of epilepsy after brain injury.
1/2021	Deletion of the Na-K-2Cl cotransporter NKCC1 results in a more severe epileptic phenotype in the intrahippocampal kainate mouse model of temporal lobe epilepsy.
1/2020	Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
1/2020	A face-to-face comparison of the intra-amygdala and intrahippocampal kainate mouse models of mesial temporal lobe epilepsy and their utility for testing novel therapies.
1/2019	Commonalities and differences in extracellular levels of hippocampal acetylcholine and amino acid neurotransmitters during status epilepticus and subsequent epileptogenesis in two rat models of temporal lobe epilepsy.
1/2019	Network pharmacology for antiepileptogenesis: Tolerability and neuroprotective effects of novel multitargeted combination treatments in nonepileptic vs. post-status epilepticus mice.
12/2018	Anticonvulsant effects after grafting of rat, porcine, and human mesencephalic neural progenitor cells into the rat subthalamic nucleus.
5/2018	Blood-Brain Barrier Leakage during Early Epileptogenesis Is Associated with Rapid Remodeling of the Neurovascular Unit.
1/2018	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?
7/2017	Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wolfgang Löscher Research Topics

Disease

140	Epilepsy (Aura) 01/2022 - 01/2002
109	Seizures (Absence Seizure) 01/2022 - 01/2002
46	Temporal Lobe Epilepsy 01/2021 - 01/2002
45	Status Epilepticus (Complex Partial Status Epilepticus) 10/2021 - 01/2002
22	Drug Resistant Epilepsy 01/2022 - 04/2002
16	Brain Diseases (Brain Disorder) 01/2022 - 01/2002
15	Neoplasms (Cancer) 06/2021 - 03/2002
14	Breast Neoplasms (Breast Cancer) 06/2015 - 03/2002
11	Partial Epilepsies (Epilepsy, Partial) 01/2021 - 07/2002
5	Brain Injuries (Brain Injury) 10/2021 - 07/2010
5	Infections 01/2021 - 08/2005
5	Nervous System Diseases (Neurological Disorders) 12/2020 - 04/2014
4	Asphyxia (Suffocation) 01/2022 - 01/2021
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 12/2015
4	Stroke (Strokes) 01/2021 - 07/2004
4	Tuberous Sclerosis (Bourneville's Disease) 12/2020 - 01/2018
3	Drug-Related Side Effects and Adverse Reactions 01/2022 - 01/2009
3	Neuralgia (Stump Neuralgia) 01/2021 - 07/2004
3	Migraine Disorders (Migraine) 01/2021 - 07/2004
3	Viral Encephalitis 11/2018 - 01/2018
3	Pain (Aches) 06/2017 - 07/2004
3	Traumatic Brain Injuries (Traumatic Brain Injury) 12/2015 - 12/2010
3	Craniocerebral Trauma (Head Injury) 04/2013 - 07/2004
2	Polyneuropathies (Polyneuropathy) 01/2022 - 06/2017
2	Glycogen Storage Disease Type II (Pompe's Disease) 12/2021 - 04/2021
2	Cognitive Dysfunction 10/2021 - 11/2016
2	Bipolar Disorder (Manic Depressive Psychosis) 01/2021 - 01/2007
2	Critical Illness (Critically Ill) 01/2021 - 12/2016
2	Wounds and Injuries (Trauma) 01/2020 - 01/2019
2	Central Nervous System Diseases (CNS Diseases) 11/2018 - 01/2005
2	Carcinoma (Carcinomatosis) 11/2018 - 01/2012

Drug/Important Bio-Agent (IBA)

77	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
75	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021 - 01/2002
30	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2022 - 04/2002
30	Kainic Acid (Kainate)IBA 01/2021 - 01/2002
27	Pilocarpine (Ocusert)FDA LinkGeneric 10/2021 - 04/2002
24	Phenobarbital (Luminal)FDA Link 01/2021 - 07/2002
18	Bumetanide (Bumex)FDA LinkGeneric 01/2022 - 06/2010
16	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2004
13	Phenytoin (Dilantin)FDA LinkGeneric 07/2017 - 09/2002
12	Levetiracetam (Keppra)FDA LinkGeneric 01/2021 - 04/2002
9	Biomarkers (Surrogate Marker)IBA 01/2020 - 03/2015
8	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2022 - 06/2013
8	GABA-A Receptors (GABA(A) Receptor)IBA 05/2016 - 07/2004
7	Valproic Acid (Depakote)FDA LinkGeneric 07/2017 - 01/2002
7	Pentylenetetrazole (Metrazol)IBA 07/2017 - 10/2008
7	Diazepam (Valium)FDA LinkGeneric 10/2016 - 10/2002
6	LithiumIBA 10/2021 - 10/2009
6	gamma-Aminobutyric Acid (GABA)IBA 01/2021 - 07/2002
6	ChloridesIBA 01/2021 - 06/2010
6	Sodium-Potassium-Chloride SymportersIBA 12/2018 - 02/2014
5	Drug CombinationsIBA 01/2022 - 12/2015
5	Protein Isoforms (Isoforms)IBA 12/2018 - 06/2013
5	AWD 131-138IBA 01/2017 - 10/2004
5	BenzodiazepinesIBA 05/2016 - 10/2004
5	tariquidar (XR9576)IBA 04/2013 - 12/2009
4	Mechanistic Target of Rapamycin Complex 1IBA 12/2020 - 01/2018
4	Sirolimus (Rapamycin)FDA Link 12/2020 - 11/2018
4	pqr620IBA 12/2020 - 01/2018
4	Neuroprotective AgentsIBA 01/2019 - 01/2002
4	Isoflurane FDA LinkGeneric 01/2018 - 02/2016
4	Lamotrigine (Lamictal)FDA LinkGeneric 07/2017 - 07/2002
4	Carbamazepine (Tegretol)FDA LinkGeneric 10/2016 - 01/2009
3	Member 2 Solute Carrier Family 12IBA 01/2022 - 01/2021
3	ezogabine (retigabine)IBA 01/2022 - 01/2002
3	Anti-Anxiety Agents (Anxiolytics)IBA 01/2022 - 01/2014
3	Aminobutyrates (Aminobutyric Acid)IBA 01/2022 - 01/2021
3	AlbuminsIBA 01/2022 - 01/2018
3	Cholinergic Agents (Cholinergics)IBA 10/2021 - 10/2009
3	DiureticsIBA 01/2021 - 02/2014
3	ProdrugsIBA 01/2021 - 06/2010
3	CytokinesIBA 01/2021 - 01/2017
3	PQR530IBA 12/2020 - 01/2018
3	trans-sodium crocetinate (crocetin)IBA 12/2020 - 11/2018
3	MTOR InhibitorsIBA 12/2020 - 01/2018
3	Topiramate (Topamax)FDA LinkGeneric 01/2020 - 11/2009
3	salicylhydroxamic acid (SHAM)IBA 11/2018 - 09/2009
3	AMPA Receptors (AMPA Receptor)IBA 01/2017 - 10/2011
3	multidrug resistance-associated protein 1IBA 10/2013 - 02/2004
3	ElacridarIBA 04/2013 - 04/2011
3	Glutamic Acid (Glutamate)FDA Link 02/2013 - 01/2002
2	Rituximab (Mabthera)FDA Link 01/2022 - 03/2019
2	Scopolamine (Hyoscine)FDA Link 10/2021 - 08/2015
2	Felbamate (Felbatol)FDA Link 01/2021 - 07/2002
2	BumepamineIBA 01/2021 - 12/2018
2	azosemideIBA 01/2021 - 01/2021
2	Everolimus FDA Link 12/2020 - 01/2018
2	Adenosine Triphosphate (ATP)IBA 12/2020 - 01/2020
2	Phosphotransferases (Kinase)IBA 11/2020 - 09/2015
2	Vigabatrin FDA Link 01/2020 - 05/2012
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019 - 04/2008
2	K Cl- CotransportersIBA 12/2018 - 06/2013
2	AntibodiesIBA 01/2018 - 04/2005
2	2,3- dioxo- 6- nitro- 7- sulfamoylbenzo(f)quinoxaline (NBQX)IBA 01/2017 - 08/2015

Therapy/Procedure

54	Therapeutics 01/2022 - 03/2002
14	Drug Therapy (Chemotherapy) 01/2022 - 03/2002
4	Electrodes (Electrode) 01/2021 - 05/2014
2	Home Infusion Therapy 12/2021 - 04/2021
2	Polypharmacy 01/2021 - 03/2015
2	Injections 01/2017 - 01/2002